SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling. Bangladesh Journal of Pharmacology, [S. l.], v. 19, n. 2, p. 52–58, 2024. DOI: 10.3329/bjp.v19i2.72787. Disponível em: https://www.banglajol.info/index.php/BJP/article/view/72787. Acesso em: 23 jun. 2026.